Jordan Bertrand
UMR 7268 ADÉS, Aix-Marseille, Université/EFS/CNRS, Espace éthique méditerranéen, hôpital d'adultes la Timone, 264, rue Saint-Pierre, 13385 Marseille Cedex 05, France ; CoReBio PACA, case 901, parc scientifique de Luminy, 13288 Marseille Cedex 09, France.
Med Sci (Paris). 2017 Oct;33(10):905-908. doi: 10.1051/medsci/20173310024. Epub 2017 Oct 10.
Since the completion of the first human DNA sequence, genomic approaches have penetrated into cancer research and therapy: first through expression profiling for diagnostic, prognostic and predictive purposes, then by sequencing of tumour DNA in order to define and apply targeted therapies. These overlapping changes occurred quite rapidly and are now overshadowed by immuno-oncology approaches that show much promise. There is however still much left to understand to make this more widely applicable, and the extreme cost of these therapies is a serious concern.
自首个人类DNA序列完成以来,基因组学方法已渗透到癌症研究和治疗领域:首先是通过表达谱分析用于诊断、预后评估和预测,然后是对肿瘤DNA进行测序以确定并应用靶向治疗。这些重叠的变化发生得相当迅速,现在却被前景广阔的免疫肿瘤学方法所掩盖。然而,要使其更广泛地应用仍有许多需要了解的地方,而且这些治疗的极高成本也是一个严重问题。